Skip to content

Remainder of 2026 at other companies

Bausch Health Companies logo
Bausch Health CompaniesBHC
Bausch + Lomb logo
Bausch + LombBLCO

Other financials

Income statement

See full
Revenue$543.9M+6.6%
Gross profit$324.7M+6.4%
Operating income$45.2M+73.1%
Net income$31.2M+120%
EPS (diluted)$0.38+111%

Balance sheet

See full
Cash & equivalents$69.6M-15.0%
Total debt$692.1M-14.0%
Total equity$898.0M+7.4%
Total assets$2.0B+0.5%

Cash flow

See full
Operating cash flow$61.7M+91.4%
CapEx$17.6M-13.1%
Free cash flow$44.1M+267%

Valuation

See full
Market cap$1.41B-22.0%
Enterprise value$2.03B-19.7%
P/E30.3×
P/S0.7×-0.3×

Profitability

See full
Gross margin58.8%+0.6pp
Operating margin3.9%+3.5pp
Net margin2.3%+1.7pp
FCF margin4.4%

Returns & leverage

See full
Return on equity5.4%+3.9pp
Debt / equity0.8×-0.2×
Current ratio0.6×+0.1×

Where this comes from

Reported directly by National Vision Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear.

The official record: National Vision Holdings, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about National Vision Holdings, Inc.'s remainder of 2026.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is National Vision Holdings, Inc.'s remainder of 2026?
National Vision Holdings, Inc. (EYE) reported remainder of 2026 of $9.94M in Q1 2026.
How has National Vision Holdings, Inc.'s remainder of 2026 changed year-over-year?
National Vision Holdings, Inc.'s remainder of 2026 decreased by 89.9% year-over-year, from $98.02M to $9.94M.